Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

NCT01529034 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT01529034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01529034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2012
Completion date
Not reported
Enrollment
175 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy